首页 正文

Clinical Trial Cancer chemotherapy and pharmacology. 2013 Dec;72(6):1223-34. doi: 10.1007/s00280-013-2287-6 Q32.32025

Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers

健康受试者中midostaurin药物-药物相互作用的Ⅰ期研究:CYP3A4介导的相互作用调查分析 翻译改进

Catherine Dutreix  1, Florence Munarini, Sebastien Lorenzo, Johannes Roesel, Yanfeng Wang

作者单位 +展开

作者单位

  • 1 Novartis Oncology, Basel, Switzerland, catherine.dutreix@novartis.com.
  • DOI: 10.1007/s00280-013-2287-6 PMID: 24085261

    摘要 Ai翻译

    Purpose: Midostaurin (PKC412), a multitargeted tyrosine kinase inhibitor that targets FMS-related tyrosine kinase 3 and KIT, is in clinical trials for the treatment for acute myeloid leukemia and advanced systemic mastocytosis. In vitro studies showed that midostaurin is predominantly metabolized by cytochrome P450 3A4 (CYP3A4) and that midostaurin inhibits and/or induces the same enzyme. Here, we address the clinical relevan... ...点击完成人机验证后继续浏览
    Copyright © Cancer chemotherapy and pharmacology. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Cancer chemotherapy and pharmacology

    缩写:CANCER CHEMOTH PHARM

    ISSN:0344-5704

    e-ISSN:1432-0843

    IF/分区:2.3/Q3

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers